Holmes Biopharma, Inc.
OTC Bulletin Board : HLMB

Holmes Biopharma, Inc.

September 27, 2005 09:00 ET

Holmes Herbs, Inc.: Qualia Completes Research Contract for Eli Lilly

SCOTTSDALE, ARIZONA--(CCNMatthews - Sept. 27, 2005) - Holmes Herbs, Inc., (OTCBB:HMHB), announced today that its clinical research partner, Qualia Clinical Research Services Inc. ("Qualia"), recently completed a clinical research contract on behalf of Eli Lilly.

The clinical research for Eli Lilly involved a Phase 4 trial on Strattera. Strattera is the first non-stimulant used to treat ADHD (attention deficit hyperactivity disorder). Eli Lilly is a leading innovation-driven worldwide pharmaceutical company.

"Qualia is establishing itself with major pharmaceutical companies and, with the financial support of Holmes Biopharma, will be aggressively expanding both the size and scope of its clinical research business in the coming months." stated Dr. Sohail Khattak, President and CEO of Qualia.

Holmes Herbs Inc. is acquiring Qualia, a transaction expected to close on or before November 30, 2005.

On behalf of the Board of Directors

John F. Metcalfe, President and CEO

Certain statements in this press release constitute "forward looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.

Contact Information